The number of measles cases worldwide surged to nearly 900,000 in 2019, and the deaths climb 50% from 2016 to 2019. To address the current measles crisis, over 95% of the world's population must be vaccinated with the required two doses of measles-containing vaccines (MCV). Detection of measles-specific IgM antibody in serum is the most common laboratory test. Creative Diagnostics has a series of measles virus antigens suitable for both IgM and IgG detection.
Fig. 1 The recombinant measles virus protein shows >90% purity by SDS-PAGE
Measles virus (MeV), is a negative-sense RNA virus with a non-segmented genome and a lipid envelope that belongs to the morbillivirus genus of the family Paramyxoviridae. The MeV genome encodes a total of eight proteins, six of which are structural proteins. The envelope has surface protrusions composed of viral hemagglutinin (H) and fusion (F) glycoproteins. H interacts with viral receptors on susceptible cells for attachment, and F interacts with H and cell membranes for fusion and entry. The helical ribonucleocapsid is formed from the genomic RNA wrapped by the nucleoprotein (N) with attached phosphoprotein (P) and large polymerase (L) proteins. The matrix (M) protein interacts with the ribonucleocapsid and the tail of the glycoprotein for the assembly of virions. C and V are non-structural proteins encoded within the P gene that regulate cellular responses to infection and modulate IFN signaling.
Fig.2 Schematic diagram of the measles virus and its genome (Aref S, et al. 2016)
Measles virus is one of the safest and most effective human vaccines, eliciting life-long protective immunity against measles after one or two low-dose inoculations. The MeV vector-based vaccine platform offers new opportunities as a replicative but safe viral vector. The MeV vector with large foreign gene insertion capacity (>6 kb) can stably express heterologous genes singly or in combination derived from other viruses. They can induce humoral and cellular responses, even if there is preexisting immunity to MeV. MeV is also developed as an oncolytic virus. Attenuated Edmonston lineage measles virus (MeV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MeV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen or the human sodium iodide symporter and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors.
| Cat_N | Target/Protein | Strain | Host/Source | |
| DAG200 | Native | Edmonston | Vero cells | Inquiry |
| DAG2298 | H protein | Menglian.Yunnan. CHN/47.09 | E. coli | Inquiry |
| DAG2317 | C protein | Schwarz | E. coli | Inquiry |
| DAG1597 | N Protein | Edmonston | E. coli | Inquiry |
| DAG1599 | F Protein | Edmonston | E. coli | Inquiry |
| DAG-P2862 | N Protein | Schwarz | S. cerevisiae | Inquiry |
